The Comparison of the Effectiveness of Dapagliflozin and Empagliflozin in the Prevention of Cardiovascular Outcomes in Patients With Type 2 Diabetes: A Network Meta-Analysis.

Cureus · 2024 · PMC11490073 · PMID 39429324

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Empagliflozin, when compared to placebo, showed a trend toward reduced atrial fibrillation risk with a risk ratio of 0.91 (95% CI: 0.75-1.10).

also in 53,322 other papers

did not reach statistical significanceno p-value reported

However, this result did not reach statistical significance.

also in 111,027 other papers

borderline significantno p-value reported

The upper bound of the confidence interval just touching 1.00 suggests a borderline significant effect.

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.